The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ptushkin V.V.

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow, Russia

Current approaches to treating thrombotic events in oncology

Authors:

Ptushkin V.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2017;6(5): 103‑106

DOI: 10.17116/onkolog201765103-106

Read: 2262 times

Download PDF (RU)
Contact the author
Table of contents

CURRENT APPROACHES TO TREATING THROMBOTIC EVENTS IN ONCOLOGY
CURRENT APPROACHES TO TREATING THROMBOTIC EVENTS IN ONCOLOGY

To cite this article:

Ptushkin VV. Current approaches to treating thrombotic events in oncology. P.A. Herzen Journal of Oncology. 2017;6(5):103‑106. (In Russ.)
https://doi.org/10.17116/onkolog201765103-106

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Study of opinions of medi­cal students on medi­cal prevention issues. Russian Journal of Preventive Medi­cine. 2024;(12):69-74
Asse­ssment of risk of deve­loping fractures and sarcopenia and quality of life of patients with chro­nic kidney disease at the outpatient stage. Russian Journal of Preventive Medi­cine. 2024;(12):88-91
Gastric cancer: inci­dence, risk factors, screening. Russian Journal of Preventive Medi­cine. 2024;(12):135-139
The rela­tionship of diet and nutrition with the frequency of migraine atta­cks. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):30-35
Prevention of periodontal inflammation in microgravity mode­ling. Stomatology. 2024;(6-2):23-28
Effe­ctiveness of risk-guided cardiac mana­gement in patients with HER2-positive breast cancer and cancer therapy-related cardiac dysfunction. Russian Cardiology Bulletin. 2024;(4-2):144-153
Obstructive sleep apnea syndrome as a predictor of atrial fibrillation. Russian Journal of Preventive Medi­cine. 2025;(1):109-114
Vita­min D role in oral cavity diseases. Stomatology. 2025;(1):81-86
Orga­nization and payment for mole­cular gene­tic analysis in patients with certain mali­gnancies in the constituent enti­ties of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):36-50
Improving the para­medic and obstetric centers heads labour responsibilities in the field of preventive measures realisation. Russian Journal of Preventive Medi­cine. 2025;(3):14-19
Abstract:

Patients with malignant neoplasms are at high risk for venous thrombosis and venous thromboembolism (VTE), which is associated with both the tumor process itself and the therapy performed. Thromboses are recognized as one of the major causes of morbidity and mortality in patients with tumors. Prolonged therapy is indicated for such patients due to the high risk of recurrence. Low-molecular-weight heparins (LMWHs) used for both the treatment and secondary prevention in cancer patients have been most investigated. LMWHs are preferred as effective and safe agents for the prevention and treatment of VTE in malignant neoplasms.

Keywords:

malignant neoplasms
thromboses
prevention
low-molecular-weight-heparins
dalteparin

Authors:

Ptushkin V.V.

S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow, Russia

Close metadata

References:

  1. Trousseau A. Phlegmasia alba dolens. In: Trousseau A, ed. Clinique medicale de l’Hotel-Dieu de Paris. Baillière. Paris; 1865: 654-712.
  2. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346(8981):1004-1005. https://doi.org/10.1016/0049-3848(95)00069-4
  3. Kakkar AK1, Chinswangwatanakul V, Tebbutt S, Lemoine NR, Williamson RC. A characterization of the coagulant and fibrinolytic profile of human pancreatic carcinoma cells. Haemostasis. 1998;28(1):1-6. https://doi.org/10.1159/000022375
  4. Luzzato G, Schafer AL. The prethrombotic state in cancer. Semin Oncol. 1990;17:147-159. https://doi.org/10.1016/0268-9499(90)90323-c
  5. Francis JL. Haemostasis and cancer. Med Lab Sci. 1989;46:331-346.
  6. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D’Aiuto G, Gulisano M, Gucciardo G, del Turco MR, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U; Italian Tamoxifen Study Group. Effect of tamoxifen on venous tromboembolic events in a breast cancer prevention Circulation. 2005;111(5):650-656.
  7. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846-1850. https://doi.org/10.1056/nejm200012213432504
  8. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, Fey MF. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88(5):745-749.
  9. Deitcher SR. Cancer and thrombosis: mechanisms and treatment. J Thromb Thrombolysis. 2003;16:21-31. https://doi.org/10.1023/b:thro.0000014589.17314.24
  10. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118(5):555-568. https://doi.org/10.1016/j.thromres.2005.10.015
  11. Gomes MP, Deitcher SR. Diagnosis of venous thromboembolic disease in cancer patients. Oncology (Williston Park). 2003;17:126-135.
  12. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310-2317. https://doi.org/10.1182/blood-2013-04-460162
  13. Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011;(6):CD006649. https://doi.org/10.1002/14651858.cd006649.pub5
  14. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikel-boom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389-2396. https://doi.org/10.1111/j.1538-7836.2011.04487.x
  15. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3,Suppl.):401S-428. https://doi.org/10.1378/chest.126.3_suppl.401s
  16. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 47. Chest. 2008;133(6,Suppl.):454S-545. https://doi.org/10.1378/chest.08-0658
  17. Kearon C, Akl EA, Comerota AJ, et al. Correction to Percentages Reported in: Prevention of VTE in Nonorthopedic Surgical Patients: American College of Chest Physicians Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2,Suppl.):419S-494. https://doi.org/10.1378/chest.141.5.1369b
  18. Robert F. The potential benefits of low-molecular-weight heparins in cancer patients. J Hematol Oncol. 2010;3:3. https://doi.org/10.1186/1756-8722-3-3
  19. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A.Recurrent venous thromboembolism and bleeding complications during anticoagulation treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. https://doi.org/10.1182/blood-2002-01-0108
  20. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153. https://doi.org/10.1056/nejmoa025313
  21. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123-2129. https://doi.org/10.1200/jco.2005.03.133
  22. Lim W. Low-molecular-weight heparin in patients with chronic renal insufficiency. Intern Emerg Med. 2008;3(4):319-323. https://doi.org/10.1007/s11739-008-0164-9
  23. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43(6):1064-1083. https://doi.org/10.1345/aph.1l194
  24. Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: The DIRECT study. Arch Intern Med. 2008;168(16):1805-1812. https://doi.org/10.1001/archinte.168.16.1805
  25. Garcia DA, Baglin TP, Weitz JI, Samama MM. American College of Chest Physicians. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2,Suppl.):24S-43.
  26. Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Exp Hematol Oncol. 2013;2(1):21. https://doi.org/10.1186/2162-3619-2-21
  27. Streiff MB, Bockenstedt PL, Cataland SR, et al. National comprehensive cancer network. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013;11(11):1402-1429.
  28. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl.6):vi85-vi92. https://doi.org/10.1093/annonc/mdr392
  29. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res. 2010;125(6):490-493. https://doi.org/10.1016/j.thromres.2009.12.023
  30. Lyman GH, Khorana AA, Kuderer NM, et al. American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189-2204. https://doi.org/10.1200/jco.2013.49.1118
  31. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062-1072. https://doi.org/10.1016/j.amjmed.2006.02.022
  32. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735. https://doi.org/10.1001/archinte.162.15.1729
  33. Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program. 2010;2010:144-149. https://doi.org/10.1182/asheducation-2010.1.144
  34. Lee AY. Treatment of established thrombotic events in patients with cancer. Thromb Res. 2012;129(Suppl.1):S146-S153. https://doi.org/10.1016/s0049-3848(12)70035-x
  35. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7(5):760-765. https://doi.org/10.1111/j.1538-7836.2009.03326.x
  36. Tun NM, Oo TH. Prevention and treatment of venous thromboembolism with new oral anticoagulants: a practical update for clinicians. Thrombosis. 2013;2013:183616. https://doi.org/10.1155/2013/183616
  37. Barbosa M. What is the best treatment for a cancer patient with thrombosis? Clin Med Insights Oncol. 2014;8:49-55. https://doi.org/10.4137/cmo.s13386
  38. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) J Thromb Haemost. 2012;10(6):1019-1025. https://doi.org/10.1111/j.1538-7836.2012.04735.x
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.